The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy

Trends Cancer. 2020 Feb;6(2):86-97. doi: 10.1016/j.trecan.2019.12.007. Epub 2020 Jan 18.

Abstract

Microbiota have emerged as key modulators of both the carcinogenic process and the immune response against cancer cells, and, thus, it seems to influence the efficacy of immunotherapy. While most studies have focused on analyzing the influence of gut microbiota, its composition substantially differs from that in the lung. Here, we describe how microbial life in the lungs is associated with host immune status in the lungs and, thus, how the identification of the microbial populations in the lower respiratory tract rather than in the gut might be key to understanding the lung carcinogenic process and to predict the efficacy of different treatments. Understanding the influence of lung microbiota on host immunity may identify new therapeutic targets and help to design new immunotherapy approaches to treat lung cancer.

Keywords: immunotherapy; lung carcinogenesis; lung microbiota.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity / drug effects
  • Animals
  • Anti-Bacterial Agents / adverse effects
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / metabolism
  • Carcinogenesis / drug effects
  • Carcinogenesis / immunology*
  • Disease Models, Animal
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / immunology
  • Dysbiosis / complications*
  • Dysbiosis / immunology
  • Dysbiosis / microbiology
  • Dysbiosis / pathology
  • Host Microbial Interactions / drug effects
  • Host Microbial Interactions / immunology
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology*
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunity, Innate / drug effects
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Inflammation / microbiology
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / microbiology
  • Lung / immunology
  • Lung / microbiology
  • Lung / pathology
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / immunology
  • Lung Neoplasms / microbiology*
  • Lung Neoplasms / mortality
  • Microbiota / drug effects
  • Microbiota / immunology*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / metabolism
  • Progression-Free Survival
  • Respiratory Mucosa / immunology
  • Respiratory Mucosa / microbiology
  • Respiratory Mucosa / pathology

Substances

  • Anti-Bacterial Agents
  • CTLA-4 Antigen
  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor